Charles River Laboratories International, Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 25, 2022; comparative periods ended June 26, 2021. The company is a non-clinical contract research organization operating through Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $973.1 million | $914.6 million | $1,887.1 million | $1,739.2 million |
| Operating income | $187.4 million | $137.6 million | $336.2 million | $261.3 million |
| Operating margin | 19.3% | 15.0% | 17.8% | 15.0% |
| Net income attributable to common shareholders | $109.3 million | $88.4 million | $202.3 million | $150.0 million |
| Diluted EPS | $2.13 | $1.72 | $3.94 | $2.93 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $252.1 million | $356.8 million |
Q2 service revenue rose 9.4% to $782.8 million; product revenue fell 4.5% to $190.3 million. Revenue growth was led by DSA and partly offset by divestitures and unfavorable foreign exchange. The filing does not provide consolidated gross margin as a headline metric.
- Q2 segments: RMS revenue grew 5.5% to $186.4 million, while operating income declined 7.2% to $39.5 million and margin fell to 21.2%. DSA revenue grew 9.6% to $591.9 million; operating income rose 23.2% to $128.8 million and margin expanded to 21.8%. Manufacturing revenue declined 1.5% to $194.8 million; operating income rose 10.2% to $62.5 million and margin expanded to 32.1%.
- Liquidity and debt at June 25, 2022: Cash and cash equivalents were $200.3 million. Current assets were $1.393 billion and current liabilities $1.048 billion. Long-term debt, net, and finance leases were $2.997 billion; revolving facility borrowings were $1.487 billion, alongside $1.5 billion of senior notes. The weighted-average debt interest rate was 3.15%.
- Six-month investment and financing: Capital expenditures were $163.3 million; net cash used in investing was $560.1 million, including $283.4 million for acquisitions. Net cash provided by financing was $258.2 million. Operating cash flow decreased year over year, principally due to working-capital timing, including customer collections, inventory purchases, and variable compensation payments.
Material changes and notable items
- Operating income increased substantially, supported by higher revenue, lower acquisition-related costs, contingent-consideration adjustments, and a favorable ruling that reversed a $17 million Cognate indirect-tax liability through SG&A. Lower unallocated corporate costs also contributed.
- Q2 other expense, net, was $39.8 million versus other income of $6.0 million a year earlier, primarily reflecting investment losses and foreign-currency losses. For the six months, other expense was $68.4 million. Venture-capital investment losses were $23.1 million for the six-month period.
- Q2 net income growth benefited from stronger operating income but was partly offset by investment losses. Six-month results also benefited from the absence of prior-year debt-extinguishment costs.
- Explora BioLabs was acquired on April 5, 2022 for a preliminary purchase price of $284.5 million, funded through the credit facility, and included in RMS. The company also acquired an additional 10% interest in a subsidiary for $15 million and redeemed Cognate’s remaining approximately 2% interest in April.
- Foreign-currency translation contributed to a $93.9 million Q2 loss in other comprehensive income; accumulated other comprehensive loss was $258.6 million at quarter-end.
Outlook, risks, and contingencies
- Management stated that cash, operating cash generation, and financing access should be sufficient to fund operations for the foreseeable future. The filing provides no specific updated revenue or earnings guidance.
- The company said it did not intend to repurchase shares for the remainder of 2022. It had $129.1 million remaining under its authorized repurchase program; shares acquired during the period were for employee tax withholding, not program repurchases.
- Management cited China COVID-related restrictions affecting client orders, staffing costs and modest inflationary pressures, and adverse foreign-exchange effects. A 10% strengthening of the U.S. dollar was estimated to reduce six-month revenue by $58.5 million and operating income by $1.0 million, all else equal.
- A 100-basis-point increase in interest rates would increase annual pre-tax interest expense by $14.9 million. The debt portfolio was primarily floating rate.
- The company has no operations in Russia or Ukraine and reported no material direct financial-statement impact through June 25, 2022, but ceased doing business with Russian customers and distributors. It warned of potential supply, cost, trade, cyber, demand, and currency disruptions.
- Various lawsuits and proceedings are pending; management does not believe their ultimate resolution will materially adversely affect the business or financial condition. Tax controversies are ongoing in several jurisdictions, with no anticipated material impact. The company also reported $17.7 million of outstanding letters of credit and $192.7 million of venture-capital commitments, of which $119.7 million had been funded.
Important facts for investors to verify
- Whether DSA demand and pricing, and the improvement in consolidated operating margin, persist as staffing and inflation costs evolve.
- How China restrictions, foreign exchange, and global supply-chain or geopolitical developments affect orders and reported results.
- Whether working-capital needs normalize and operating cash flow supports acquisition spending and elevated capital expenditures.
- Debt levels, variable-rate exposure, and liquidity following the Explora acquisition and other investment commitments.
- The durability of earnings excluding favorable tax and contingent-consideration adjustments, as well as volatile investment and foreign-currency gains or losses.